Navigation Links
Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment
Date:7/23/2008

LA JOLLA, Calif., July 23 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA) ("Duska") announced today that it has submitted for comment a synopsis of a proposed Phase 3 clinical study for its lead drug, ATPace(TM), to the U.S. Food and Drug Administration's (the "FDA") Division of Cardiovascular and Renal Products.

Based on recent communications with the FDA, including a face-to-face meeting held on April 16, 2008, Duska believes that the proposed single, prospective, placebo-controlled, and randomized trial in patients presenting to the emergency room with paroxysmal supraventricular tachycardia (PSVT) should be sufficient to demonstrate clinical safety and efficacy. The proposed primary endpoint of the study is dose-dependent conversion of PSVT to normal sinus rhythm. The FDA has expressed willingness to review and comment on the proposed trial design according to the Special Protocol Assessment (SPA) procedure.

PSVT is a rapid regular heart rate originating in the atria. It has been estimated that there are 89,000 new cases of PSVT per year in the United States alone. PSVT is one of the most common cardiac arrhythmias.

Duska has already compiled clinical data on the safety and efficacy of adenosine triphosphate (ATP), which is the active pharmaceutical ingredient in ATPace(TM), in the treatment of patients with PSVT. In addition, Duska has its own safety database on ATPace(TM), which was obtained in Phase 1 and 2 clinical trials. Based on these data, Duska believes that upon successful completion of the proposed Phase 3 trial, it would have all the clinical data necessary to support the filing of the NDA for ATPace(TM) under section 505(b)(2), the drafting of which has already commenced.

Dr. James Kuo, Duska's Chairman and CEO, said, "After our recent interactions with the FDA, I believe we have a clear plan to acquire all the data that would be necessary to support the filing of a NDA for ATPace(TM)
'/>"/>

SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Duska Therapeutics Obtains Standard & Poors Listing
2. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
3. CV Therapeutics to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008
4. Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008
5. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
6. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
7. Organizational Changes at Silence Therapeutics
8. Genzyme Corporation and PTC Therapeutics Announce Collaboration on Small Molecule for Genetic Diseases
9. Arno Therapeutics Announces New Ticker Symbol
10. Lorus Therapeutics Receives $600 Thousand From Escrow Account
11. Silence Therapeutics Announces Successful Opposition of Glover Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... (PRWEB) December 23, 2014 ... series is designed to introduce cutting edge ... users and partners of platform upgrades. This ... benefits; empowering users in their quest to ... tools. , According to SoundConnect’s Marketing Manager, ...
(Date:12/24/2014)... 2014 The report provides ... its definition, classification, application and industry overview. ... process, and product cost structure. Production is ... analysis also covers upstream raw materials, equipment, ... trend and proposals. In the end, the ...
(Date:12/24/2014)... 2014 Pipette.com announces their Holiday ... can submit their #HolidayInTheLab pictures for a chance to ... , For those struggling to think of a holiday ... in the Lab Contest provides the ideal holiday presents. ... to send pictures of their chemistree, holiday sweaters, as ...
(Date:12/24/2014)... 23, 2014 PharmaBoardroom,s new ... today and available for free download , digs deep ... and growth in the sector today. One area ... has been in developing a homegrown pharmaceutical manufacturing base, even ... still remains some way off. A cursory comparison with neighboring ...
Breaking Biology Technology:SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3
... 2011 Psoriasis is a persistent, long-lasting chronic skin ... more than 125 million individuals.  For some, it is ... On a continuing quest to find more effective ... Journal of Investigative Dermatology reported that the ...
... 14, 2011 Merriman Capital, ... (NASDAQ: MERR ), today announced that it ... Circadian Technologies Limited (ASX: CIR; OTCQX: CKDXY) as it ... http://photos.prnewswire.com/prnh/20100914/SF64919LOGO ) Circadian is an Australian biotechnology ...
... June 14, 2011 OncoSec Medical Inc. (OTCBB: ... to treat solid tumor cancers, announced today two ... the clinical operations of OncoSec,s ElectroOncology therapies. ... Dhillon, OncoSec,s President and CEO, said, "OncoSec has ...
Cached Biology Technology:Actinobac Biomed, Inc. Demonstrates In Vivo Efficacy for Psoriasis Treatment 2Merriman Capital Announces Sponsorship of Circadian Technologies on OTCQX 2Merriman Capital Announces Sponsorship of Circadian Technologies on OTCQX 3OncoSec Announces Clinical Leadership Appointments 2OncoSec Announces Clinical Leadership Appointments 3OncoSec Announces Clinical Leadership Appointments 4
(Date:12/10/2014)... CIE San Diego has launched an innovative ... tissue that enhances care coordination among social service and ... information; earned a second $1 million grant from the ... aging in community and; will be recognized as a ... 4-6p. CIE San Diego today announced ...
(Date:12/10/2014)... California , December 9, 2014 ... with ITN,s BCARD Platform   ... cloud-based enterprise meeting scheduling solutions for business-to-business (B2B) ... the world leader in mobile near-field communication (NFC), ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a ... $2.3 million in Series A1 funding led by UK-based ... also participated in the investment round. "We ... healthcare community adopts next-generation sequencing and seeks new approaches ... Reid Robison , MD MBA, and CEO of ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... showed that they could cut the lives of disease-carrying mosquitoes ... from fruit flies. Now, a new report in the December ... suggests that their strategy might do one better: The Wolbachia ... viruses that are a growing threat to humans, including those ...
... Scientists have shown for the first time that insects, ... They made the discovery thanks to high-speed video cameras ... that they used to film desert locusts stepping along ... new light on insects, ability to perform complex tasks, such ...
... Glaciers along the Gulf of Alaska are enriching stream and ... carbon contained in glacial runoff, researchers from four universities and ... issue of the journal Nature *. In ... Environmental Science Program at the University of Alaska Southeast, set ...
Cached Biology News:New tool in the fight against mosquito-borne disease: A microbial 'mosquito net' 2Ladder-walking locusts show big brains aren't always best 2Glacier melt adds ancient edibles to marine buffet 2
... the biological data hidden in your samples with ... allows you to create your own microarray designs ... your own pace and receive delivery of your ... is a secure, online array creation application tool ...
Acetylcholinesterase (human brain, AChE)...
... meets the demands of the routine trace ... from reliable, robust and simple to use ... in the most challenging sample matrices found ... suited to the toughest analytical challenges found ...
C1-inhibitor (C1-INH)...
Biology Products: